

CME AGENDA

All times are listed in Pacific Time (PT).

Saturday, March 25, 2023

Session I: HBV

2:00 – 2:05 PM	Welcome
2:05 – 2:25 PM	HBV Overview of the Last 3 Years for Drug Development: Phase 2-3 <i>Ira Jacobson, MD</i>
2:25 – 2:50 PM	Emerging Therapies in the Next 3 Years (Pre-clinical Phase 1) <i>Jorg Petersen, MD (Virtual)</i>
2:50 – 3:15 PM	What Are the Most Promising Immunomodulatory Therapies for HBV Infection? <i>Adam J. Gehring, PhD</i>
3:15 – 3:30 PM	Emerging Concepts and Data CPAMS Third and Fourth Generation <i>Man-Fung Yuen, MBBS, MD, PhD, DSc</i>
3:30 – 4:15 PM	Panel Discussion
4:15 – 4:35 PM	Break
4:35 – 4:50 PM	Stopping All Therapy in HBV Clinical Trials: What Should Be the Criteria for Discontinuation <i>Nezam H. Afdhal, MD (Virtual)</i>
4:50 – 5:05 PM	Is There a Real Difference between ETV and TDF TAF? Relapse? HCC? <i>W. Ray Kim, MD</i>
5:05 – 5:20 PM	Does the New Data on HBV DNA Integration and HBsAg Production Effect the Design and Definition of Treatment Endpoints of Phase II and Phase III Studies? <i>Ju-Tao Guo, MD (Virtual)</i>
5:20 – 5:35 PM	How Do We Fit FNA and Liver Biopsy into HBV Drug Development and Design? Should All Studies Have FNA Subset and Examine Intrahepatic Immune Activity? CccDNA? Integrants? <i>Adam J. Gehring, PhD</i>
5:35 – 6:05 PM	Panel Discussion
6:05 – 6:10 PM	Closing Remarks
6:10 – 8:00 PM	Reception

This activity is jointly provided by the Purdue University College of Pharmacy and the Chronic Liver Disease Foundation.

This activity is supported by an educational grant from Gilead Sciences, Inc.

Sunday, March 26, 2023

6:30 – 7:00 AM Breakfast

Session II: HDV

7:00 – 7:20 AM	HDV Update: Review of the Last 3 Years, Including Epi, Testing, Linkage to Care <i>Robert Gish, MD</i>
7:20 – 7:40 AM	New Insights into the Biology of HDV: Implications for Drug Development <i>Emmanuel Gordien, MD, PhD (Virtual)</i>
7:40 – 7:55 AM	Should All Patients with HDV Be Treated? <i>Tatyana Kushner, MD, MSCE</i>
7:55 – 8:10 AM	What Is the Current Role of Interferon Therapy for HDV? <i>Christopher Koh, MD, MHSc, FACP, FAASLD (Virtual)</i>
8:10 – 8:25 AM	Break
8:25 – 8:45 AM	How Should Bulevirtide Be Used in Clinical Practice? <i>Pietro Lampertico, MD, PhD (Virtual)</i>
8:45 – 9:05 AM	What Other Therapies Are Being Developed for HDV Infection? NAPS, Lambda, and Lonafarnib <i>Heiner Wedemeyer, MD (Virtual)</i>
9:05 – 10:05 AM	Panel Discussion
10:05 – 10:10 AM	Closing Remarks
10:10 AM	Adjourn

This activity is jointly provided by the Purdue University College of Pharmacy and the Chronic Liver Disease Foundation.

This activity is supported by an educational grant from Gilead Sciences, Inc.